Redose
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the peptide signal the hypothalamus uses to prompt the pituitary gland to secrete growth hormone (GH). It exists in two distinct forms: one carrying a Drug Affinity Complex (DAC) modification for extended action, and one without it (often labeled Mod GRF 1-29) for shorter, pulse-like activity. Neither form is approved for clinical use; both remain investigational compounds of interest to researchers studying GH physiology and body composition.
What is CJC-1295
CJC-1295 is a 30-amino-acid peptide derived from the first 29 residues of endogenous GHRH, with several amino acid substitutions that improve metabolic stability compared to the native hormone. Natural GHRH is broken down rapidly by the enzyme dipeptidyl peptidase IV (DPP-IV), giving it a half-life measured in minutes. The structural modifications in CJC-1295 resist this degradation. The with-DAC variant goes a step further: the DAC group forms a covalent bond with circulating albumin, using the protein as a carrier reservoir that releases the peptide gradually over days.
The two forms serve different research applications:
| Form | Common label | Approximate half-life | Typical injection frequency |
|---|---|---|---|
| CJC-1295 with DAC | CJC-1295 DAC | 6-8 days | Once or twice weekly |
| CJC-1295 without DAC | Mod GRF 1-29 | 30 min to 2 hours | Multiple times per week |
How it works
Both forms act on the same receptor: the GHRH receptor on pituitary somatotroph cells. Binding triggers a cyclic AMP signaling cascade that stimulates GH secretion. Because CJC-1295 amplifies the body's own GH release mechanism rather than supplying synthetic GH directly, GH output retains some of the normal feedback regulation via somatostatin. This is considered a meaningful distinction from exogenous GH administration, though long-term physiological consequences are not fully characterized.
Elevated circulating GH then acts on the liver to increase production of insulin-like growth factor 1 (IGF-1). IGF-1 is the mediator responsible for many of the downstream effects on protein synthesis, adipose tissue metabolism, bone turnover, and cellular repair.
The no-DAC form, dosed more frequently and in smaller amounts, is theorized to produce GH pulses that more closely resemble the body's natural ultradian rhythm. The with-DAC form produces a more continuous, blunted elevation. Whether one pattern is clinically superior for any particular outcome has not been established in controlled human trials.
What the research says
The most frequently cited human study of CJC-1295 (PMID 16352683) enrolled healthy adults across single and multiple ascending dose cohorts. Key findings included:
- A mean estimated half-life of approximately 5.8 to 8.1 days for the with-DAC form.
- Mean GH levels increased 2 to 10 fold above baseline following injection.
- Mean IGF-1 levels remained elevated above baseline for up to 28 days after multiple doses.
- No serious adverse reactions were reported at the doses studied.
That study was a Phase I/II pharmacokinetic and pharmacodynamic investigation, not a definitive efficacy trial. Outcomes such as fat loss, muscle gain, or recovery improvement were not the primary endpoints. Extrapolating the pharmacokinetic data to specific performance or body composition benefits requires caution.
Animal studies and in-vitro work have added mechanistic support for GH and IGF-1 pathway involvement in muscle protein synthesis and lipolysis, but translating those findings directly to human outcomes remains speculative without dedicated clinical trials. The evidence base for CJC-1295 in humans is narrow compared to approved GH-axis therapies.
Typical dosing
The following ranges appear in published research and in reported off-label protocols. They are provided for informational context only and are not a recommendation or medical instruction.
CJC-1295 with DAC: The human pharmacokinetic study used doses ranging from 30 to 300 mcg/kg body weight. Reported practical protocol dosing is commonly cited between 1 and 2 mg per injection, once or twice per week, administered subcutaneously.
CJC-1295 without DAC (Mod GRF 1-29): Reported protocol ranges commonly cited between 100 and 300 mcg per injection, administered subcutaneously, typically two to three times per week or more frequently. When paired with a ghrelin mimetic, both peptides are often injected at the same time before a fasting period to capitalize on the natural GH pulse window.
Dosing varies meaningfully across sources, protocols have not been standardized in clinical settings, and individual responses differ. Anyone considering peptide protocols should work with a qualified healthcare provider and seek compounded preparations from a licensed pharmacy.
For practical injection preparation, see the guide on how to reconstitute peptides, and for rotating administration sites, see injection site rotation.
Side effects and safety
In the primary published human study, the compound was described as generally well tolerated and no serious adverse reactions were noted. Across the broader protocol and clinical literature, commonly reported adverse effects include:
- Injection site reactions: Transient redness, mild swelling, or discomfort at the injection site.
- Flushing and warmth: A brief sensation of warmth or skin flushing shortly after injection, thought to relate to vasodilation.
- Water retention: Mild fluid retention, sometimes noticed as puffiness in the extremities or face, attributed to GH's effects on renal sodium handling.
- Headache: Reported occasionally, typically mild and transient.
- Fatigue: Some users report temporary fatigue, particularly early in a protocol.
- Hypoglycemia risk: GH can transiently affect insulin sensitivity; injecting near meals or during a fed state may modify this effect.
Longer-term safety in humans has not been characterized in rigorous trials. Sustained elevation of IGF-1 carries theoretical concerns including cellular proliferation effects, potential impact on insulin resistance, and cardiovascular considerations. People with a personal or family history of hormone-sensitive conditions, diabetes, or active malignancy should be particularly cautious. CJC-1295 is not approved, and using it without medical supervision carries unquantified risk.
The compound is not approved for anti-aging, athletic performance, or cosmetic purposes. Regulatory authorities in multiple countries classify GHRH analogs as prohibited in competitive sport.
Tracking CJC-1295 with Redose
If you are using CJC-1295 as part of a supervised research protocol or clinical program, Redose makes the tracking side frictionless. Log each injection in one tap, with injection site, dose amount, and time recorded automatically. The vial inventory tracker shows remaining doses and flags when to reorder, and the built-in calculators at /calculators handle reconstitution math and unit conversions so you are not doing it by hand. Download Redose at /#download.
This profile is educational information, not medical advice. Talk to a qualified healthcare provider before starting any protocol.